Overview
Updated 14 Jul 2026
Richard D. Kim, M D, is Professor of Oncology at H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. The public record shows 348 publications with 6,200 citations (h-index 37), centered on Colorectal Cancer Treatments and Studies, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 49 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 49 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 116.
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
InvestigatorPhase 2RecruitingNCT06553885 - Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
InvestigatorRecruitingNCT05830279 - A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
Sponsor: ImStem Biotechnology
InvestigatorPhase 1Active, not recruitingNCT04956744
Industry payments
Updated 14 Jul 2026
49 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year20253 payments
- PFIZER INC.Program year20254 payments
- Exelixis Inc.Program year202513 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Jul 2026
141 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- A multicenter, open-label study of RP2 oncolytic immunotherapy expressing anti–CTLA-4 in combination with second-line atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) or in combination with first-line durvalumab in advanced biliary tract cancer (BTC).
ASCO Annual Meeting
ASCO2026Presenting author - A phase II study of enfortumab vedotin in patients with advanced or metastatic colorectal cancer or hepatocellular carcinoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits.
International journal of cancer
2026 - Critique on "Real-World Effectiveness of First-Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights" [Response to Letter].
Pragmatic and observational research
2024
Most-cited worksby citation count (OpenAlex)
- 01The Role of Angiogenesis in Hepatocellular Carcinoma548 citations2018
- 02
- 03Pulmonary Nontuberculous Mycobacterial Disease449 citations2008
- 04Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy346 citations2017
- 05
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
12902 USF Magnolia Dr, Tampa, FL 33612
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- MD
University of Miami School of Medicine (combined 6-year BS/MD program)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Internal Medicine Residency
University of Illinois at Chicago
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Fellowship in Hematology and Medical Oncology
Yale University Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Board Certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership rolesjournal and society appointments
- Ad hoc editorial reviewer: Journal of Clinical Oncology
Annals of Oncology, Cancer, and Lancet Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Awards & honorshonors on the public record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
Secondary affiliationsappointments beyond the home institution
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗
- Former Clinical Assistant Professor
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
2010provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globaloncologyacademy.org ↗ - Associate Professor / Professor
University of South Florida (USF) Morsani College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Media & interviewspress, podcasts and appearances
- OncLive video series (multiple appearances): commentary on HCC research at Moffitt
regorafenib in metastatic colorectal cancer, immunotherapy in colorectal cancer, and retifanlimab in anal cancer (SCAC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Contributing author/interviewee
GI Oncology Now
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gioncologynow.com ↗ - Featured speaker
VJOncology (video interviews on GI malignancies)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by otherswhere others cite or feature them
- X / Twitter
x.com/MoffittNews/status/1796527140969587027
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Rami Komrokji, MD
Moffitt Cancer Center
- 1,527
- publications
- 69
- h-index
- 14
- trials
Melissa Alsina, MD
Moffitt Cancer Center
- 561
- publications
- 64
- h-index
- 12
- trials
Alberto Chiappori, MD
Moffitt Cancer Center
- 257
- publications
- 48
- h-index
- 13
- trials